

## PRESS RELEASE

### Hemcheck has received a first order from the university hospital Charité in Berlin

Hemcheck has received a first small order from the university hospital Charité in Berlin. Charité is one of the largest university hospitals in Europe with a budget of approximately EUR 2.3 billion. The order concerns bgs-Test and is of lower economic value.

- It is very positive with a first order from Charité. The hospital is a very large university hospital and a reference hospital for many other possible customers both in Germany and internationally. We of course hope that this can be the start of a longer collaboration with Charité, says Joen Averstad, acting CEO of Hemcheck.

**For further information contact:**

Hemcheck Sweden AB (publ)  
Joen Averstad, acting CEO  
Tel: +46 76 108 8191  
Email: [joen.averstad@hemcheck.com](mailto:joen.averstad@hemcheck.com)

**About Charité**

<https://www.charite.de/en/>

**About Hemcheck**

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, [info@fnca](mailto:info@fnca), is the Certified Adviser to the company.